u/TherealCarbunc

4 theses · first seen Oct 20, 2026

Window	Theses	Resolved	Wins	Win rate	Avg return	Median return
1d	3	3	3	100%	+7.3%	+4.1%
3d	4	4	3	75%	+5.8%	+5.8%
1w	4	4	3	75%	+15.1%	+1.4%
1m	4	4	2	50%	+8.8%	+16.0%
3m	4	4	2	50%	-20.3%	-8.9%
6m	4	4	0	0%	-49.1%	-46.0%
1y	1	1	0	0%	-87.7%	-87.7%

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$DFLIr/pennystocksTechnical Analysisbullish

u/TherealCarbunc · 341d ago3 prior · 50% at 3mo

DFLI, technical analysis of the days chart.

Daily and weekly chart patterns (ascending triangle and falling wedge) suggest a bullish reversal after dilution-driven selling pressure abates. A decisive break above resistance at $0.83–$0.85 would signal buyer control and likely trigger upside, though the author notes a 17–36% failure rate if buying volume dries up.

At post $62.96Now $1.90-97.0% since postedas of Oct 30, 4:45 PM ET

1d+14.0%

3d+7.8%

1w-0.6%

1m-48.0%

3m-68.5%

6m-72.8%

1y—

original post →

$NFEr/pennystocksDDbullish

u/TherealCarbunc · 343d ago3 prior · 50% at 3mo

Long 1,800 shares of NFE

NFE, it's at the tipping point. (not pumping)

NFE is at an inflection point where two catalysts—FOMB final approval for Puerto Rico revenue and successful debt restructuring—could unlock value. Shorts are heavily overextended with CTB >90%, and the author sees better odds of upside (75%) than downside (40%) if catalysts align, though execution risk is high.

At post $1.21Now $4.92+306.6% since postedas of Oct 30, 4:45 PM ET

1d—

3d-7.4%

1w+0.8%

1m-3.3%

3m+0.8%

6m-50.4%

1y—

original post →

$FEMYr/pennystocksBullishbullish

u/TherealCarbunc · 362d ago3 prior · 50% at 3mo

FEMY, original post removed due to no summary of the article posted

FDA approval for final FemBloc trial phase combined with $12M secured financing and potential $58M in additional warrant proceeds signals strong upside. Author expects stock to establish a baseline above $1 based on C-1 warrant exercise prices, supported by surging volume and decreasing short availability.

At post $13.14Now $1.37-89.6% since postedas of Oct 30, 4:45 PM ET

1d+4.1%

3d+18.9%

1w+58.3%

1m+35.3%

3m-18.6%

6m-41.6%

1y—

original post →

$FEMYr/pennystocksBullishbullish

u/TherealCarbunc · 373d ago3 prior · 50% at 3mo

“6.3k shares at an average of .64 (about 4k invested); recent tactical trim of ~900 profits and rebuy for more shares with plan to trim on significant surges and rebuy at lower prices, eventually holding and adding to position long-term”

FEMY; my longterm bullish stance

FemBloc is a non-invasive permanent contraception procedure replacing tubal ligation with 95% effectiveness, lower cost (~$2500 cheaper), EMA/MEDSAFE approval, and a potential addressable market of 1.2M annual procedures. The author projects 20-38x upside over 3-10 years as the product becomes a new healthcare standard with no current competitors and multiple other FDA-approved revenue streams from Femasys.

At post $12.18Now $1.37-88.8% since postedas of Oct 30, 4:45 PM ET

1d+3.9%

3d+3.9%

1w+2.0%

1m+51.1%

3m+4.9%

6m-31.5%

1y-87.7%

original post →

End of results.